Benign formation of mcb 10. Benign lung tumors

Brief information from the international classification of diseases 10 for lung cancer and other malignant tumors of the pulmonary system.

ICD-10 code for lung cancer

C34.0 - all types of malignant tumors of the lung and bronchi.

• C34.0- main bronchi
• C34.1- upper lobe
• C34.2– average share
• C34.3- lower lobe
• C34.8- defeat of several localizations
• C34.9- unspecified localization

Higher classification

C00-D48– neoplasms

C00-C97– malignant

C30-C39- respiratory and thoracic organs

Add-ons

In this system, classification occurs only by localization. Many are looking into which category peripheral cancer may fall into. The answer is to any of the above, depending on the location of the carcinoma in the lung.

Another common question is where to classify metastases in the classification. The answer is that they are not included here. The presence of metastases already occurs in the same TNM classification. Where M is just the fact of the presence or absence of neoplasms.

The next one is central cancer. We refer to C34.2 by localization in the middle lobe of the lung.

Cancer of the main bronchi is already reflected - C34.0.

The classifier also does not take into account the left-right localization of the disease. Only from top to bottom.

Lungs' cancer

We will not repeat ourselves, we have already made a very detailed review of a malignant lung tumor in. Read, watch, ask questions. It is there that you can read about the factors, signs, symptoms, diagnosis, treatment, prognosis and other important information regarding the whole disease.

Diagnosis code C00-D48 includes 4 clarifying diagnoses (ICD-10 headings):

1. C00-C97 - Malignant neoplasms
   Contains 15 blocks of diagnoses.
2. D00-D09 Neoplasms in situ
   Contains 9 blocks of diagnoses.
   Includes: Bowen's disease erythroplasia morphological codes with pattern code /2 erythroplasia Queyrat.
3. D10-D36 - Benign neoplasms
   Contains 27 blocks of diagnoses.
   Included: morphological codes with pattern code /0.
4. D37-D48 - Neoplasms of uncertain or unknown nature
   Contains 12 blocks of diagnoses.

Explanation of the disease with the code C00-D48 in the MBK-10 reference book:

Notes

1. Malignant neoplasms, primary, ill-defined and unspecified sites
   Categories C76-C80 include malignancies with an ill-defined primary site or those defined as "disseminated", "disseminated" or "spread" without indication of the primary site. In both cases, the primary localization is considered as unknown.
2. functional activity
   Class II is classified as neoplasms, regardless of the presence or absence of functional activity in them. If it is necessary to clarify the functional activity associated with a particular neoplasm, an additional code from class IV can be used. For example, catecholamine-producing adrenal malignant pheochromocytoma is coded under C74 with an additional code E27.5; basophilic pituitary adenoma with Itsenko-Cushing's syndrome is coded by heading D35.2 with an additional code E24.0.
3. Morphology
   There are a number of large morphological (histological) groups of malignant neoplasms: caracinomas, including squamous and adenocarcinomas; sarcomas; other soft tissue tumors, including mesothelioma; lymphomas (Hodgkin's and non-Hodgkin's); leukemia; other refined and localization-specific types; unspecified cancers. The term "cancer" is generic and can be used for any of the above groups, although it is rarely used in relation to malignant neoplasms of the lymphoid, hematopoietic and related tissues. The term "carcinoma" is sometimes incorrectly used as a synonym for the term "cancer".
   In class II, neoplasms are classified mainly by localization within broad groupings based on the nature of the course. In exceptional cases, morphology is indicated in the headings and subheadings.
   For those wishing to identify the histological type of neoplasm on p. 577-599 (vol. 1, part 2) provides a general list of individual morphological codes. Morphological codes are taken from the second edition of the International Classification of Diseases in Oncology (ICD-O), which is a biaxial classification system that provides independent coding of neoplasms by topography and morphology.
   Morphological codes have 6 characters, of which the first four determine the histological type, the fifth indicates the nature of the course of the tumor (malignant primary, malignant secondary, i.e. metastatic, in situ, benign, indeterminate), and the sixth character determines the degree of differentiation of solid tumors and is also used as a special code for lymphomas and leukemias.
4. Use of subcategories in class II
   Attention is drawn to the special use in this class of the subcategory marked.8 (see note 5). Where it is necessary to distinguish a subcategory for the group "others", a subcategory is usually used.7.
5. Malignant neoplasms extending beyond one site and the use of a subcategory with a fourth character.8 (lesion extending beyond one or more of the specified sites)
   Headings C00-C75 classify primary malignant neoplasms according to their site of origin. Many three-character rubrics are further subdivided into subcategories according to the different parts of the organs concerned. A neoplasm that involves two or more contiguous sites within a three-character rubric, and whose site of origin cannot be determined, should be classified in a subcategory with a fourth character.8 (a lesion that extends beyond one or more of the above sites), unless such a combination is specifically indexed elsewhere headings. For example, carcinoma of the esophagus and stomach would be coded C16.0 (cardia), while carcinoma of the tip and underside of the tongue should be coded as C02.8. On the other hand, carcinoma of the tip of the tongue involving the lower surface of the tongue should be coded to C02.1 because the site of origin (in this case, the tip of the tongue) is known.
   The term "lesion extending beyond one or more of the above locations" implies that the areas involved are contiguous (one continues the other). The subcategory numbering sequence often (but not always) corresponds to the anatomical neighborhood of the sites (eg bladder C67.-) and the coder may be forced to refer to anatomical reference books to determine the topographic relationship.
   Sometimes the neoplasm goes beyond the localizations indicated by three-digit rubrics within one organ system. The following subcategories are provided for coding such cases:
   C02.8 Tongue involvement extending beyond one or more of the above locations
   C08.8 Involvement of major salivary glands extending beyond one or more of the above sites
   C14.8 Involvement of lips, oral cavity and pharynx extending beyond one or more of the above sites
   C21.8 Involvement of rectum, anus [anus] and anal canal extending beyond one or more of the above sites
   C24.8 Biliary tract disorder extending beyond one or more of the above sites
   C26.8 Gastrointestinal disorder extending beyond one or more of the above sites
   C39.8 Involvement of respiratory and thoracic organs extending beyond one or more of the above sites
   C41.8 Bone and articular cartilage disorder extending beyond one or more of the above locations
   C49.8 Connective and soft tissue disorder extending beyond one or more of the above locations
   C57.8 Disorders of female genital organs extending beyond one or more of the above sites
   C63.8 Disorder of male genital organs extending beyond one or more of the above sites
   C68.8 Urinary disorders extending beyond one or more of the above sites
   C72.8 Disorders of the brain and other parts of the central nervous system extending beyond one or more of the above locations
   An example would be carcinoma of the stomach and small intestine, which should be coded to C26.8 (disease of the digestive system extending beyond one or more of the above sites).
6. Malignant neoplasms of ectopic tissue
   Malignancies of ectopic tissue should be coded according to the site mentioned, eg ectopic malignancy of the pancreas should be coded as pancreatic, unspecified (C25.9).
7. Use of the Alphabetical Index when coding neoplasms
   When coding neoplasms, in addition to their localization, the morphology and nature of the course of the disease should be taken into account and, first of all, it is necessary to refer to the Alphabetical Index for a morphological description. Volume 3's introductory pages include general instructions for using the Alphabetical Index. In order to ensure the correct use of the rubrics and subcategories of Class II, special indications and examples relating to neoplasms should be taken into account.
8. Use of the second edition of the International Classification of Diseases in Oncology (ICD-0)
   For some morphological types, class II provides a rather narrow topographic classification, or none at all. The ICD-0 topographical codes are used for all neoplasms with essentially the same three- and four-digit rubrics used in Class II for malignant neoplasms (C00-C77, C80), thereby providing greater localization accuracy for other neoplasms [malignant secondary ( metastatic), benign, in situ, uncertain or unknown].
   Thus, institutions interested in determining the location and morphology of tumors (such as cancer registries, cancer hospitals, pathology departments, and other services specialized in oncology) should use ICD-0.

This class contains the following broad groups of neoplasms:

• C00-C75 Malignant neoplasms of specified localizations, which are designated as primary or presumably primary, except for neoplasms of lymphoid, hematopoietic and related tissues
  • C00-C14 Lips, oral cavity and pharynx
  • C15-C26 Digestive organs
  • C30-C39 Respiratory and thoracic organs
  • C40-C41 Bones and articular cartilage
  • C43-C44 Skin
  • C45-C49 Mesothelial and soft tissues
  • C50 Mammary gland
  • C51-C58 Female reproductive organs
  • C60-C63 Male reproductive organs
  • C64-C68 Urinary tract
  • C69-C72 Eyes, brain and other parts of the central nervous system
  • C73-C75 Thyroid and other endocrine glands
• C76-C80 Malignant neoplasms of ill-defined, secondary and unspecified sites
• C81-C96 Malignant neoplasms of lymphoid, hematopoietic and related tissues that are designated as primary or suspected primary
• C97 Malignant neoplasms of independent (primary) multiple localizations
• D00-D09 In situ neoplasms
• D10-D36 Benign neoplasms
• D37-D48 Neoplasm of uncertain or unknown nature [see note on p. 242]

This class contains the following broad groups of neoplasms:

• C00-C97 Malignant neoplasms
  • C00-C75 Malignant neoplasms of specified sites designated as primary or suspected primary, excluding neoplasms of lymphoid, hematopoietic and related tissues
    • C00-C14 Lips, oral cavity and pharynx
    • C15-C26 Digestive organs
    • C30-C39 Respiratory and thoracic organs
    • C40-C41 Bones and articular cartilage
    • C45-C49 Mesothelial and soft tissues
    • C50-C50 Breast
    • C51-C58 Female reproductive organs
    • C60-C63 Male reproductive organs
    • C64-C68 Urinary tract
    • C69-C72 Eyes, brain and other parts of the central nervous system
    • C73-C75 Thyroid and other endocrine glands
  • C76-C80 Malignant neoplasms of ill-defined, secondary and unspecified sites
  • C81-C96 Malignant neoplasms of lymphoid, hematopoietic and related tissues that are designated as primary or suspected primary
  • C97-C97 Malignant neoplasms of independent (primary) multiple sites
• D00-D09 In situ neoplasms
• D10-D36 Benign neoplasms
• D37-D48 Neoplasms of uncertain or unknown nature

Notes

1. Malignant neoplasms, primary, ill-defined and unspecified sites

2. Morphology

   There are a number of large morphological (histological) groups of malignant neoplasms: caracinomas, including squamous and adenocarcinomas; sarcomas; other soft tissue tumors, including mesothelioma; lymphomas (Hodgkin's and non-Hodgkin's); leukemia; other refined and localization-specific types; unspecified cancers.
   The term "cancer" is generic and can be used for any of the above groups, although it is rarely used in relation to malignant neoplasms of the lymphoid, hematopoietic and related tissues. The term "carcinoma" is sometimes incorrectly used as a synonym for the term "cancer".

   In class II, neoplasms are classified mainly by localization within broad groupings based on the nature of the course. In exceptional cases, morphology is indicated in the headings and subheadings.

   For those wishing to identify the histological type of neoplasm, a general list of individual morphological codes is given. Morphological codes are taken from the second edition of the International Classification of Diseases in Oncology (ICD-O), which is a biaxial classification system that provides independent coding of neoplasms by topography and morphology.

   Morphological codes have 6 characters, of which the first four determine the histological type, the fifth indicates the nature of the course of the tumor (malignant primary, malignant secondary, i.e. metastatic, in situ, benign, indeterminate), and the sixth character determines the degree of differentiation of solid tumors and is also used as a special code for lymphomas and leukemias.

3. Use of subcategories in class II

   Attention is drawn to the special use in this class of the subcategory marked.8 (see note 5). Where it is necessary to distinguish a subcategory for the group "others", a subcategory is usually used.7.

4. Malignant neoplasms extending beyond one site and the use of a subcategory with a fourth character.8 (lesion extending beyond one or more of the specified sites)

5. Use of the Alphabetical Index when coding neoplasms

   When coding neoplasms, in addition to their localization, the morphology and nature of the course of the disease should be taken into account and, first of all, it is necessary to refer to the Alphabetical Index for a morphological description.

6. Use of the second edition of the International Classification of Diseases in Oncology (ICD-0)

   For some morphological types, class II provides a rather narrow topographic classification, or none at all. The ICD-0 topographical codes are used for all neoplasms with essentially the same three- and four-digit rubrics used in Class II for malignant neoplasms (C00-C77, C80), thereby providing greater localization accuracy for other neoplasms [malignant secondary ( metastatic), benign, in situ, uncertain or unknown].

   Thus, institutions interested in determining the location and morphology of tumors (such as cancer registries, cancer hospitals, pathology departments, and other services specialized in oncology) should use ICD-0.

last modified: January 2016

If necessary, use an additional code (U85) to identify resistance, immunization, and refractive properties of the neoplasm to anticancer drugs.

last modified: January 2012

Note. Many in situ neoplasms are seen as successive morphological changes between dysplasia and invasive cancer. For example, three grades are recognized for cervical intraepithelial neoplasia (CIN), of which grade three (CIN III) includes both severe dysplasia and carcinoma in situ. This system of gradations is extended to other organs, such as the vulva and vagina. Descriptions of grade III intraepithelial neoplasia with or without indication of severe dysplasia are presented in this section; grades I and II are classified as dysplasias of the organ systems involved and should be coded to the classes corresponding to those organ systems.

Included:

• Bowen's disease
• erythroplasia
• morphological codes with the code of the nature of the neoplasm /2
• erythroplasia of Queira

Includes: morphological codes with behavioral code /0

Note. Categories D37-D48 are classified by location of neoplasms of uncertain or unknown nature (ie, neoplasms that raise doubts as to whether they are malignant or benign). In the classification of tumor morphology, such neoplasms are encoded by their nature with the code /1.

Clinical manifestations of benign lung tumors depend on the location of the neoplasm, its size, direction of growth, hormonal activity, degree of bronchial obstruction, and complications caused.
Benign (especially peripheral) lung tumors may not give any symptoms for a long time. In the development of benign lung tumors are distinguished:
asymptomatic (or preclinical) stage.
stage of initial clinical symptoms.
the stage of severe clinical symptoms due to complications (bleeding, atelectasis, pneumosclerosis, abscess pneumonia, malignancy and metastasis).
With peripheral localization in the asymptomatic stage, benign lung tumors do not manifest themselves. In the stage of initial and severe clinical symptoms, the picture depends on the size of the tumor, the depth of its location in the lung tissue, and the relationship to the adjacent bronchi, vessels, nerves, and organs. Large lung tumors can reach the diaphragm or chest wall, causing pain in the chest or heart area, shortness of breath. In case of vascular erosion by the tumor, hemoptysis and pulmonary hemorrhage are observed. Compression of the large bronchi by a tumor causes a violation of bronchial patency.
Clinical manifestations of benign lung tumors of central localization are determined by the severity of bronchial patency disorders, in which grade III is distinguished:
I degree - partial bronchial stenosis;
II degree - valvular or valve bronchial stenosis;
III degree - bronchial occlusion.
In accordance with each degree of violation of bronchial patency, the clinical periods of the disease differ. In the 1st clinical period, corresponding to partial bronchial stenosis, the lumen of the bronchus is narrowed slightly, so its course is often asymptomatic. Sometimes there is a cough, with a small amount of sputum, less often with an admixture of blood. General health is not affected. Radiologically, a lung tumor is not detected in this period, but can be detected by bronchography, bronchoscopy, linear or computed tomography.
In the 2nd clinical period, valvular or valve stenosis of the bronchus develops, associated with obstruction by the tumor of most of the lumen of the bronchus. With valve stenosis, the lumen of the bronchus partially opens on inspiration and closes on expiration. In the part of the lung ventilated by the narrowed bronchus, expiratory emphysema develops. There may be a complete closure of the bronchus due to edema, accumulation of blood and sputum. In the lung tissue located on the periphery of the tumor, an inflammatory reaction develops: the patient's body temperature rises, cough with sputum, shortness of breath, sometimes hemoptysis, chest pain, fatigue and weakness appear. Clinical manifestations of central lung tumors in the 2nd period are intermittent. Anti-inflammatory therapy relieves swelling and inflammation, leads to the restoration of pulmonary ventilation and the disappearance of symptoms for a certain period.
The course of the 3rd clinical period is associated with the phenomena of complete occlusion of the bronchus by the tumor, suppuration of the atelectasis zone, irreversible changes in the area of ​​the lung tissue and its death. The severity of symptoms is determined by the caliber of the bronchus obstructed by the tumor and the volume of the affected area of ​​the lung tissue. There is a persistent fever, severe chest pain, weakness, shortness of breath (sometimes asthma attacks), poor health, cough with purulent sputum and blood, and sometimes pulmonary bleeding. X-ray picture of partial or complete atelectasis of a segment, lobe or entire lung, inflammatory and destructive changes. On linear tomography, a characteristic picture is found, the so-called "bronchial stump" - a break in the bronchial pattern below the obturation zone.
The speed and severity of bronchial obstruction depends on the nature and intensity of lung tumor growth. With peribronchial growth of benign lung tumors, clinical manifestations are less pronounced, complete occlusion of the bronchus rarely develops.